Healthcare / Diagnostics & ResearchSão Paulo
$3.09
+0.07 (+2.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-510.6M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.9B
P/E
N/A
•EV/EBITDA
4.9x
↓ROE
-16.8%
↓Gross Margin
30.4%
↓Debt/Equity
1.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.2%
FCF CAGR
—
FCF margin
-2.9%
FCF / Net income
0.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.17B · net income $-1.15B · FCF $-326.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.17B | $11.17B | $15.32B | $14.25B | $13.13B |
| Net Income | $-1.15B | $-1.15B | $-1.20B | $-1.17B | $-386.9M |
| EBITDA | $2.04B | $2.04B | $1.99B | $2.09B | $2.21B |
| EPS | -0.92 | -0.92 | -0.96 | -1.56 | -0.69 |
| Gross Margin | 30.4% | 30.4% | 27.4% | 27.3% | 28.9% |
| Operating Margin | 9.1% | 9.1% | 6.6% | 6.4% | 8.0% |
| Net Margin | -10.3% | -10.3% | -7.8% | -8.2% | -2.9% |
| Balance Sheet | |||||
| Debt/Equity | 1.29 | 1.29 | 1.64 | 1.81 | 1.96 |
| Current Ratio | 1.30 | 1.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-326.6M | $-326.6M | $-510.6M | $-1.77B | $-1.17B |
| Returns | |||||
| ROE | -16.8% | -16.8% | -15.1% | -15.9% | -5.5% |
| Valuation | |||||
| EV/EBITDA | 4.92 | 4.92 | 6.90 | 9.02 | 9.10 |
| P/B | 0.56 | 0.56 | 0.31 | 0.98 | 1.06 |
| Growth & Yield | |||||
| Revenue Growth | -27.1% | -27.1% | 7.5% | 8.6% | — |
| EPS Growth | 3.9% | 3.9% | 38.5% | -125.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+94.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.96 → -0.92
Residual
+94.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.